Citations

Clear

186 citation(s) found for "Frantz, R".

Superior Capsular Reconstruction: A Salvage Option for Massive Irreparable Rotator Cuff Tears with Pseudoparalysis or Subscapularis Insufficiency
Ulrich, Marisa N. , Frantz, Travis L. , Jones, Grant L. , Bishop, Julie Y. , Cvetanovich, Gregory L. , Barlow, Jonathan D. , Everhart, Joshua Scott

Mayo Clinic

Arthroscopy | May 27, 2021 | Volume: 38 | Issue: 2 | Pages: 253-261

10.1016/j.arthro.2021.05.018 | PMID 34052375 Get It

Purpose We sought to examine superior capsular reconstruction (SCR) outcomes after minimum 2‐year follow‐up and determine risk factors that were predictive of outcomes. Methods Forty consecutive patients (mean age 57.3 years, 87.5% male) who underwent SCR for massive irreparable rotator cuff tears (RCT) met the inclusion criteria. Minimum 2‐year follow‐up was obtained for 32 patients (80% follow‐up). Patient demographics and preoperative clinical findings were collected. Postoperative data, including complications, patient satisfaction, strength and range‐of‐motion (ROM), and patient‐reported outcomes were collected. Results The Hamada score was ≤2 in 88% with average acromiohumeral interval distance of 6.8 mm. Preoperatively, 6 patients had external rotation lag (19%) and 6 had pseudoparalysis (19%). Intraoperative assessment of the subscapularis demonstrated true insufficiency in 38%. There was significant improvement in forward elevation (FE) (31° increase; P = .007) and strength in all planes (all P < .05). Patient‐reported outcomes significantly improved (American Shoulder and Elbow Surgeon [ASES] 34‐point increase; visual analog scale [VAS] 2.9‐point decrease; single alpha‐numeric evaluation [SANE] 48‐point increase; all P < .05). Twenty‐six patients (81%) were completely or somewhat satisfied with surgery. At time of final follow‐up, 3/32 patients (9%) failed SCR and converted to reverse total shoulder arthroplasty. There were 4 (13%) reported complications (2 patients had postoperative falls; 1 patient had persistent severe pain; 1 had persistent stiffness). One patient was deceased. Patients with pseudoparalysis ( n = 6) had significant improvement in post‐operative FE (28 vs 154°; P < .0001) and SANE score ( P = .016) with 66% patient satisfaction. However, outcome scores overall remained lower than SCR without pseudoparalysis. Regarding subscapularis insufficiency ( n = 12), significant improvement was seen in postoperative FE (108 vs 158°; P = .019) and patient‐reported outcome scores ( P < .005). In patients converted from SCR to reverse total shoulder arthroplasty ( n = 3), there were no distinguishing characteristics present. Conclusion Superior capsular reconstruction is an effective salvage operation for massive irreparable RCT. Patients with pseudoparalysis or subscapularis insufficiency demonstrate significant postoperative improvement in FE and patient‐reported outcomes. Level of Evidence IV, retrospective cohort.
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
DuBrock, Hilary M. , Bartolome, Sonja, Feldman, Jeremy P., Ivy, D. Dunbar , Rosenzweig, Erika B. , Sager, Jeffrey S., Presberg, Kenneth W., Mathai, Stephen C. , Klinger, James R. , Eggert, Michael, Marco, Teresa De , Elwing, Jean , Badesch, David B., Bull, Todd M., Cadaret, Linda , Ramani, Gautam , Thenappan, Thenappan , Ford, H. James , Al‐Naamani, Nadine , Mazimba, Sula , Runo, James , Chakinala, Murali M. , Ryan, John , Krowka, Michael J. , Investigators, PHAR, Rosenzweig, Erika B , Klinger, James R , DuBrock, Hilary M , Thenappan, Thenappan , Al-Naamani, Nadine , Mathai, Stephen C , Burger, Charles D. , Lammi, Matthew R. , Simon, Marc A. , Horn, Evelyn M. , Frantz, Robert P. , Investigators, PHAR

Mayo Clinic

Pulmonary Circulation | May 17, 2021 | Volume: 11 | Issue: 3 | Pages: 1-10

10.1177/20458940211020913 | PMID 34158918 Get It

Compared to idiopathic pulmonary arterial hypertension (IPAH), patients with portopulmonary hypertension (POPH) have worse survival. Health disparities may contribute to these differences but have not been studied. We sought to compare socioeconomic factors in patients with POPH and IPAH and to determine whether socioeconomic status and/or POPH diagnosis were associated with treatment and health‐care utilization. We performed a cross‐sectional study of adults enrolled in the Pulmonary Hypertension Association Registry. Patients with IPAH (n = 344) and POPH (n = 57) were compared. Compared with IPAH, patients with POPH were less likely to be college graduates (19.6% vs. 34.9%, p = 0.02) and more likely to be unemployed (54.7% vs. 30.5%, p < 0.001) and have an annual household income below poverty level (45.7% vs. 19.0%, p < 0.001). Patients with POPH had similar functional class, quality of life, 6‐min walk distance, and mean pulmonary arterial pressure with a higher cardiac index. Compared with IPAH, patients with POPH were less likely to receive combination therapy (46.4% vs. 62.2%, p = 0.03) and endothelin receptor antagonists (28.6% vs. 55.1%, p < 0.001) at enrollment with similar treatment at follow‐up. Patients with POPH had more emergency department visits (1.7 ± 2.1 vs. 0.9 ± 1.2, p = 0.009) and hospitalizations in the six months preceding enrollment (1.5 ± 2.1 vs. 0.8 ± 1.1, p = 0.02). Both POPH diagnosis and lower education level were independently associated with a higher number of emergency department visits. Compared to IPAH, patients with POPH have lower socioeconomic status, are less likely to receive initial combination therapy and endothelin receptor antagonists but have similar treatment at follow‐up, and have increased health‐care utilization.
Abstract 14817: Assessing the Burden of Cardiovascular Risk Factors and Disease Across PVDOMICS Cohorts
Larive, Brett , Jacob, Miriam , Group, PVDOMICS Study, Leopold, Jane A. , Rosenzweig, Erika B. , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Rischard, Franz , Horn, Evelyn M. , Group, PVDOMICS Study

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.14817 Get It

Longitudinal trends demonstrate an increase in the prevalence of cardiovascular (CV) risk factors in the general population; however, the burden of CV risk factors or established disease in patients across WSPH groups remains unknown. Accordingly, we examined the prevalence of CV risk factors and established disease in the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) cohort. PVDOMICS enrolled 1,097 subjects with pulmonary hypertension (PH) (mPA ≥ 25 mmHg) and at-risk disease comparators (mPa < 25 mmHg) from six US centers. Compared to participants with PH attributable to left heart disease (LHD-PH; WSPH Group 2, n=145) who are expected to have a high burden of CV risk factors and disease, patients with WSPH Groups 1,3,4,and 5 (non-LHD-PH)(n=618) were younger (56.2 ± 14.5 vs 67.7 ± 11.7 yrs, p<0.02) with no difference in %female or race. Non-LHD-PH had a lower prevalence of the CV disease risk factors hypertension (38.6% vs. 66.7%, p<0.02), diabetes mellitus (21.4 vs. 41.0%, p<0.02), and metabolic syndrome (30.8 vs. 48.4%, p<0.02) compared to LHD-PH, while smoking, hypercholesterolemia, and family history of CV disease were similar between groups. The prevalence of established CV disease, including myocardial infarction, CABG or stent, stroke, arrhythmia, or peripheral arterial disease was significantly lower in non-LHD-PH than in LHD-PH. At right heart catheterization, although mPA pressures were similar between the groups, PVR (5.5[3.3, 8.7] vs. 3.7[7.2, 5.7] WU, p<0.02), and cardiac output were higher (5.4 ± 1.9 vs. 4.9 ± 1.6 L/min, p<0.02) in non-LHD-PH compared to LHD-PH. This corresponded to a higher left ventricular ejection fraction by echo (62.2 ± 8.2 vs. 54.0 ± 14.0 %, p<0.02) and greater 6-minute walk distance (361.8 ± 134.7 vs. 294.7 ± 118.7 m, p<0.02). Non-LHD-PH also had better cardiovascular health compared to LHD-PH with higher modified American Heart Association Life’s Simple 7 scores (6.7 ± 1.6 vs. 5.8 ± 1.5, P<0.02). Taken together, these data demonstrate that CV disease risk factors and CV disease are frequent comorbidities that occur in patients with non-LHD-PH, although CV health is not as impaired as in patients with LHD-PH. How this affects PH-related outcomes remains to be determined.
The SPECTRA Study: A Phase 2a Single-Arm, Open-Label, Multicenter Exploratory Study to Assess the Effects of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
Manimaran, Solaiappan , Lu, Jinchang , Waxman, Aaron B. , Risbano, Michael G. , Frantz, Robert P. , Rischard, Franz

Mayo Clinic

D3. D003 COME TOGETHER - CLINICAL ADVANCES IN PULMONARY HYPERTENSION: LESSONS FROM BEST ABSTRACTS | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1187-A1187

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1187 Get It

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights from the Pulmonary Hypertension Association Registry
Chang, Kevin Y. , Badesch, D.B., Bull, T.M., Chakinala, Murali M. , Marco, Teresa De , Mathai, S.C., Ryan, J.J., Mathai, Stephen C. , Mathai, Stephen C , Duval, Sue , Frantz, Robert P. , Hemnes, Anna R. , Rosenzweig, Erika B. , Thenappan, Thenappan

Mayo Clinic

D3. D003 COME TOGETHER - CLINICAL ADVANCES IN PULMONARY HYPERTENSION: LESSONS FROM BEST ABSTRACTS | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1181-A1181

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1181 Get It

An Automated Screening Algorithm Using Electrocardiograms for Pulmonary Hypertension
Wagner, Tyler , Asirvatham, S, Babu, Mittapalli Jeevan, Barve, Rakesh , Carlson, Katherine , Carpenter, Corinne , Friedman, Paul A. , Prasad, A., Chehoud, C., Kogan, E., Nnewihe, A., Quinn, D., Bridges, C., Soundararajan, V., DuBrock, Hilary M. , Wagner, T., Attia, Zachi I. , Awasthi, Samir , Frantz, Robert P. , Kogan, E. I. , Kapa, Suraj

Mayo Clinic

D3. D003 COME TOGETHER - CLINICAL ADVANCES IN PULMONARY HYPERTENSION: LESSONS FROM BEST ABSTRACTS | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1179-A1179

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1179 Get It

Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry
Chakinala, Murali M. , Rane, D., Oudiz, R.J., Frost, Adaani , Nathan, S.D., Frantz, Robert P. , Farber, Harrison W.

Mayo Clinic

TP14. TP014 DIAGNOSTIC AND SCREENING INSIGHTS IN PULMONARY, CRITICAL CARE, AND SLEEP | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1594-A1594

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1594 Get It

A Phase 1b, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects with WHO Group 1 Pulmonary Arterial Hypertension
Highland, K.B., McConnell, J.W. , Burger, C.D., Roscigno, R.F., Cravets, Matt , McCaffrey, Robert J. , Zisman, Lawrence S. , Frantz, Robert P. , Howard, Luke

Mayo Clinic

TP82. TP082 LET IT BE - CLINICAL ADVANCES IN PULMONARY VASCULAR DISEASE: PAH AND BEYOND | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A3602-A3602

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3602 Get It

Prevalence and Impact of Chronic Kidney Disease Among Patients with Chronic Thromboembolic Pulmonary Hypertension: An Analysis of the Pulmonary Hypertension Association Registry
Shlobin, Oksana A. , DeMarco, Teresa , Raval, Abhijit, Chakinala, Murali M. , Mazimba, Sula , Valle, Kathryn T. del , Frantz, Robert P. , Leary, Peter J. , DuBrock, Hilary M.

Mayo Clinic

TP88. TP088 LUCY IN THE SKY WITH DIAMONDS - PULMONARY EMBOLISM, CTEPH, THROMBOSIS, AND COVID19: CLINICAL ADVANCES | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A3716-A3716

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3716 Get It

Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
Maron, Bradley A. , Abman, Steven H. , Elliott, C. Gregory , Hopper, Rachel K. , Nicolls, Mark R. , Shlobin, Oksana A. , Kovács, Gábor , Olschewski, Horst , Olschewski, Horst , Frantz, Robert P. , Horn, Evelyn M. , Shah, Sanjiv J , Rosenzweig, Erika B.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 16, 2021 | Volume: 203 | Issue: 12 | Pages: 1472-1487

10.1164/rccm.202012-4317so | PMID 33861689 Get It

Abstract The diagnosis and management of pulmonary arterial hypertension (PAH) includes several advances, such as a broader recognition of extrapulmonary vascular organ system involvement, validated point-of-care clinical assessment tools, and focus on the early initiation of multiple pharmacotherapeutics in appropriate patients. Indeed, a principal goal in PAH today is an early diagnosis for prompt initiation of treatment to achieve a minimal symptom burden; optimize the patient’s biochemical, hemodynamic, and functional profile; and limit adverse events. To accomplish this end, clinicians must be familiar with novel risk factors and the revised hemodynamic definition for PAH. Fresh insights into the role of developmental biology (i.e., perinatal health) may also be useful for predicting incident PAH in early adulthood. Emergent or underused approaches to PAH management include a novel TGF-β ligand trap pharmacotherapy, remote pulmonary arterial pressure monitoring, next-generation imaging using inert gas–based magnetic resonance and other technologies, right atrial pacing, and pulmonary arterial denervation. These and other PAH state of the art advances are summarized here for the wider pulmonary medicine community.